Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Bode

Showing results (591-600 of 600) with videos related to

Pageof 60
Sort By:
You have reached the last page of results.This site can display upto 600 results.
European Heart Journal|September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trialC Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Circulation|March 26, 2014
Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in miceDennis Wolf, Felix Jehle, Nathaly Anto Michel, et al.
Membranes|March 6, 2021
Outcome Prediction in Patients with Severe COVID-19 Requiring Extracorporeal Membrane Oxygenation-A Retrospective International Multicenter StudyAlexander Supady, Jeff DellaVolpe, Fabio Silvio Taccone, et al.
Lancet (London, England)|November 9, 2015
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trialA Michael Lincoff, Roxana Mehran, Thomas J Povsic, et al.
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
The New England Journal of Medicine|November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromesPierluigi Tricoci, Zhen Huang, Claes Held, et al.
Thrombosis and Haemostasis|April 15, 2020
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on ThrombosisElisa d'Alessandro, Christian Becker, Wolfgang Bergmeier, et al.
Pageof 60

Showing results (591-600 of 600) with videos related to

Sort By:
Pageof 60
You have reached the last page of results.This site can display upto 600 results.
European Heart Journal|September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trialC Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Circulation|March 26, 2014
Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in miceDennis Wolf, Felix Jehle, Nathaly Anto Michel, et al.
Membranes|March 6, 2021
Outcome Prediction in Patients with Severe COVID-19 Requiring Extracorporeal Membrane Oxygenation-A Retrospective International Multicenter StudyAlexander Supady, Jeff DellaVolpe, Fabio Silvio Taccone, et al.
Lancet (London, England)|November 9, 2015
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trialA Michael Lincoff, Roxana Mehran, Thomas J Povsic, et al.
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
The New England Journal of Medicine|April 8, 2024
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionC Michael Gibson, Danielle Duffy, Serge Korjian, et al.
Journal of the American College of Cardiology|April 8, 2024
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIThomas J Povsic, Serge Korjian, M Cecilia Bahit, et al.
The New England Journal of Medicine|November 15, 2011
Thrombin-receptor antagonist vorapaxar in acute coronary syndromesPierluigi Tricoci, Zhen Huang, Claes Held, et al.
Thrombosis and Haemostasis|April 15, 2020
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on ThrombosisElisa d'Alessandro, Christian Becker, Wolfgang Bergmeier, et al.
Pageof 60